Background Perioperative diabetic ketoacidosis (DKA) with near-normal blood glucose
concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated …

Although the recommended preoperative cessation period for sodium-glucose cotransporter
2 inhibitors (SGLT2is) changed in 2020 (from 24 h to 3–4 days preoperatively) to reduce the …

Bariatric surgery has been shown to have a variety of metabolically beneficial effects for
patients with type 2 diabetes (T2D), and is now also called metabolic surgery. At the 2nd …

Bariatric/metabolic surgery and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are
becoming increasingly popular for the management of overweight/obese patients with type 2 …

Treating type 2 diabetes mellitus (T2DM) in patients with obesity remains a challenge for
physicians, endocrinologists and surgeons, a fact supported by uncontroverted evidence …

Abstract Purpose of Review In this review, the authors discuss potential clinical applications
for continuous ketone monitoring (CKM) in a broad continuum of clinical settings from pre …

Abstract Purpose of Review The number of bariatric surgeries for patients with type 1 or type
2 diabetes continues to grow. Clinicians are challenged to choose therapies that reach …

Abstract Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are antihyperglycemic drugs
that are currently being recommended as second-line therapy for patients with diabetes …

Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are glucose-lowering agents
being increasingly used for cardio-renal protection in patients with or without type 2 diabetes …

Introduction Very low-calorie diets (VLCDs) are used preoperatively in bariatric-metabolic
surgery; however, this can lead to physiological ketosis. Euglycemic ketoacidosis is an …